Last reviewed · How we verify
GSK2110183 IR Tablet
At a glance
| Generic name | GSK2110183 IR Tablet |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Continuation Study of the Oral AKT Inhibitor GSK2110183 (PHASE2)
- Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2110183 IR Tablet CI brief — competitive landscape report
- GSK2110183 IR Tablet updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI